Odyssey Therapeutics Appoints Timothy P. Walbert and Ian F. Smith to Board of Directors
Key Highlights Timothy P. Walbert: Former Chairman, President & CEO of Horizon Therapeutics, instrumental in $28.3 billion acquisition…
Browsing Tag
Gary D. Glick
4 posts
Odyssey Therapeutics Appoints William Roush, Ph.D., as EVP and Head of Small Molecule Research
Key Highlights Dr. William Roush appointed EVP and head of small molecule research. Focus on advancing small molecule…
Odyssey Therapeutics Bolsters Leadership Team
Key Highlights Julie Clauss, MBA, appointed as Chief Operating Officer, bringing extensive biotech and pharmaceutical leadership experience. Christopher…
Odyssey Therapeutics Secures $101 Million in Series C Funding to Propel Immunomodulators and Oncology Medicines
Key Highlights Odyssey Therapeutics, Inc. completes a significant $101 million Series C financing round led by Ascenta Capital. The funding will…